Within the Singapore biomedical landscape, French pharmaceutical leader Sanofi has launched its second manufacturing facility in Tuas Biomedical Park—an $800 million investment poised to redefine vaccine production. Known as “Modulus”, this 58,000 sq. m facility is the world’s first modular vaccine plant, designed to rapidly switch between different biopharmaceutical products using 34 interconnected production modules.
- JML is proud to have played a role in this project, contributing to the successful execution of Phase 1 from June 2022 to June 2024. Their scope encompassed full Mechanical, Electrical, Instrumentation, and Extra Low Voltage (ELV) works, marking our first foray into the pharmaceutical sector. This fast-track project demanded parallel engineering and construction efforts, requiring agility, precision, and close collaboration with Sanofi and global equipment suppliers.
- Despite facing significant challenges—including a three-month delay in civil works—our team rose to the occasion. Through a comprehensive constructability study and meticulous coordination with multiple contractors, we managed to avoid clashes in the complex engineering and construction environment. Our team’s commitment enabled us to deliver comprehensive documentation packages (VTOP and CTOP) in line with Good Documentation Practices (GDP) and eventually hand over the project in time.
- Our performance and dedication in Phase 1 have earned us the trust of our client, leading to the award of Phase 2, which will run from March 2025 to December 2025. This phase will mirror the scope of Phase 1, reinforcing our role as a key partner in bringing Modulus to full operational capacity by mid-2026.
- As Sanofi prepares to hire 200 professionals in engineering, data analysis, and technology, we are honored to contribute to a project that not only advances global health but also strengthens Singapore’s position as a hub for biomedical innovation.
